XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment

The following table provides the operating expenses of our clinical stage drug development segment for the three and nine months ended September 30, 2025 and 2024 (rounded to the nearest $00):

 

   Three months ended
September 30,		   Nine months ended
September 30,		 
   2025   2024   2025   2024 
Clinical Study Expense  $1,083,100   $2,345,300   $9,823,300   $7,105,400 
Other Research Expense   852,800    5,956,400    3,386,000    19,262,700 
Manufacturing and Drug Storage Expense   752,000    301,400    989,200    1,275,400 
Pre-clinical Expense   
-
    
-
    
-
    33,700 
Compensation Expense   990,400    805,300    2,986,500    2,478,300 
Stock-based Compensation Expense   358,000    1,740,700    1,621,700    5,020,000 
Total Research and Development Expense  $4,036,300   $11,149,100   $18,806,700   $35,175,500